Transitory-Tex-CNI contributed to GVL effects after PD-1 blockade. (A-C, E-H, K-L) Lethally irradiated B6 mice received transplantation with TCD-BM combined with purified T cells from BALB/c donors and administered with CSP or vehicle from days 0 to 14 after allo-HCT. Recipient mice were IV injected with 5 × 10⁴ (CSP-treated recipients) or 1 × 10⁶ (vehicle-treated recipients) C1498-luc cells on day 7 after allo-HCT. (A-C) Recipients were intraperitoneally injected with αPD-L1 twice a week from days 14 to 42 after allo-HCT. (A) A schematic overview of the experiments. (B) Leukemia growth was evaluated using bioluminescence imaging weekly after leukemia injection. (C) Survival curves of recipients (n = 9 per group). (D) Histograms show PD-L1 expression on various mouse leukemia cells. (E-J) In P815 group, lethally irradiated B6D2F1 mice received transplantation with TCD-BM combined with purified T cells from B6 donors and administered with CSP from days 0 to 14 after allo-HCT. Recipient mice were IV injected with 5 × 10⁴ P815 cells on day 7 after allo-HCT. Proportions (E) and absolute numbers (F) of PD-1⁺TIGIT^– cells, and proportions (G) and absolute numbers (H) of Ly6C⁺ cells in CD8⁺ donor T cells on day 16 after allo-HCT (n = 5 per group). P815-innoculated (I-J) and C1498-innoculated (K-L) recipients were intraperitoneally injected with αPD-L1 or PBS on day 14 after allo-HCT. Proportions of Ki-67 (I,K) and GZMB (J,L) expression in CD8⁺ donor T cells on day 16 after allo-HCT (n = 5 per group). (C) Data from 2 independent experiments were combined and shown as means ± SEM. (E-L) Data from one of 2 similar experiments were shown as means ± SEM. ∗P < .05; ∗∗P < .01; ∗∗∗P < .005. ns, not significant.